This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroToday Home
Video Lectures
Clinical Trials For My Patients - Prostate Cancer Videos
Comparing Industry-Sponsored and Investigator-Initiated Trials in Genitourinary Oncology - Srikala Sridhar
Urologic Oncology Clinical Trials: Size, Scope, and Impact - Kristian Stensland
Tarlatamab Shows Encouraging Activity in Phase 1 Trial in DLL3-Positive Neuroendocrine Prostate Cancer - Rahul Aggarwal
Moonshot Initiative Funds Study on PSA-Based Risk-Stratified Prostate Cancer Screening - Siobhan Sutcliffe
The Southern California Research Forum: Advancing GU Cancer Care - Monty Pal & Rana McKay
Metastasis-directed Radiotherapy (MDRT) for Men With De-novo Oligometastatic Prostate Cancer Treated With Long-term ADT (METANOVA)
ESCAPE TRIAL - Evaluation of PSMA PET-CT in Active Surveillance for Prostate CancEr
INDICATE Trial Seeks to Clarify Role of PET Scans in Prostate Cancer Recurrence - Neha Vapiwala
LuTectomy Study Shows Promise: Targeted Radiation Safe Before Prostate Cancer Surgery - Michael Hofman & Renu Eapen
The ECLIPSE Phase III Trial of Lutetium PSMA-I&T Shows Promise in Advanced Prostate Cancer Treatment - Emmanuel Antonarakis
Fractionated 225Ac-J591 for Progressive mCRPC in Patients with Prior Treatment with 177Lu-PSMA - Jones Nauseef
Phase II Trial of Salvage Radiation Therapy for Prostate Cancer in Four Weeks Versus Five Days (SHORTER)
Feasibility Study of Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)
NRG-GU 010 Phase III Trial: Tailored Prostate Cancer Treatment Based on Decipher Risk Score (GUIDANCE) PART 3
NRG-GU 010 Phase III Trial: Tailored Prostate Cancer Treatment Based on Decipher Risk Score (GUIDANCE) PART 2
NRG-GU 010 Phase III Trial: Tailored Prostate Cancer Treatment Based on Decipher Risk Score (GUIDANCE) PART 1
Safety and Feasibility of a Shorter Course of Radiation Therapy for Men with Low or Intermediate Risk Prostate Cancer (FORT)
The Combination of Enzalutamide Plus Talazoparib for Patients With Castration-Sensitive Metastatic Prostate Cancer With HRR Gene Alterations (TALAPRO-3) - Neeraj Agarwal
LuTectomy, a Single-Arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Radical Prostatectomy - Declan Murphy & Renu Eapen
Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence - UroToday Journal Club - Christopher Wallis & Zachary Klaassen
Sabizabulin in Phase 1b/2 Clinical Trials of Men With Metastatic Castration-Resistant Prostate Cancer Who Progressed on Androgen Receptor-Targeting Agents - Mark Markowski
Darolutamide plus ADT in Metastatic Hormone-Sensitive Prostate Cancer - The ARASEC Trial - Neal Shore
Real-World Understanding of the Prevalence of Potentially Targetable DNA Damage Repair Alterations – The PROMISE Registry – Heather Cheng
ARANOTE - Darolutamide in Addition to ADT Vs. ADT in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) - Fred Saad
Sabizabulin in Men with Metastatic Castration Resistant Prostate Cancer - Mark Markowski
A Trial of VERU-100 for the Treatment of Advanced Prostate Cancer – Ronald Tutrone
PSMAfore Trial - Evaluating 177Lu-PSMA-617 in Chemotherapy-Naïve mCRPC Patients – Michael Morris
Evaluating the Efficacy of Sabizabulin in The Treatment of Metastatic Castration-Resistant Prostate Cancer – Robert Dreicer
Single Priming Dose of 177Lu-PSMA-617 Followed by Pembrolizumab in mCRPC in a Phase 1b Trial - Rahul Aggarwal
Talazoparib for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations (TALAPRO-1) Journal Club - Christopher Wallis & Zachary Klaassen
Differences in the Pattern of and the Response to Treatment Not Just Race - Elisabeth Heath
Evaluating the Benefit of Rucaparib and Enzalutamide Combination Therapy Vs. Enzalutamide Alone for the Treatment of mCRPC - the Phase III CASPAR Trial - Arpit Rao
Intensive Androgen Deprivation in High-Risk Biochemically Recurrent Prostate Cancer Patients - Alliance Foundation Trial (AFT19) - Rahul Aggarwal
Implementing Prostate Cancer Working Group 3 Criteria in Clinical Trials- Michael Morris and Lawrence Schwartz
The DORA Trial, Comparing Overall Survival in Patients Treated with Docetaxel vs. Docetaxel plus Radium-223 - Michael Morris
Count Me In! The Metastatic Prostate Cancer Project - Eliezer Van Allen
A Study Evaluating Optimal Use of Radioactive Drugs for Prostate Cancer Therapy - Misha Beltran
Current Landscape of Prostate Cancer Clinical Trials - Alliance Cooperative Group - Michael J. Morris
STARTAR Trial: Systemic Therapy in Salvage Setting for Prostate Cancer- Tian Zhang
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
